Clinical trials: Primary Central Nervous System Lymphoma (PCNSL)
Primary Central Nervous System Lymphoma (PCNSL)
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
- Trial name
- NCT04688151
- Testing
- Rituximab
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Health Research Institutes, Taiwan
Lymphoma
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00082836
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Primary Central Nervous System Lymphoma
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT02836158
- Testing
- R-IDARAM plus intrathecal chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Navy General Hospital, Beijing
Primary Central Nervous System Lymphoma
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival.
- Trial name
- OptiMATe (NCT04931368)
- Testing
- Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix, Control intervention: four courses of MATRix
- Where
- Germany
- Volunteers
- 331 people
- Sponsor
- Klinikum Stuttgart